Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mannkind Corp
(NQ:
MNKD
)
5.710
-0.010 (-0.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,685,541
Open
5.720
Bid (Size)
5.620 (5)
Ask (Size)
5.770 (2)
Prev. Close
5.720
Today's Range
5.640 - 5.770
52wk Range
3.170 - 6.040
Shares Outstanding
264,305,532
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker
June 27, 2024
Our first-ever twin bill.
Via
The Motley Fool
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
June 22, 2024
From
MannKind
Via
GlobeNewswire
Performance
YTD
+45.66%
+45.66%
1 Month
+17.49%
+17.49%
3 Month
+36.28%
+36.28%
6 Month
+69.94%
+69.94%
1 Year
+30.07%
+30.07%
More News
Read More
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
June 05, 2024
From
MannKind
Via
GlobeNewswire
Earnings Scheduled For February 27, 2024
February 27, 2024
Via
Benzinga
MannKind Earnings Preview
February 26, 2024
Via
Benzinga
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
May 29, 2024
From
MannKind
Via
GlobeNewswire
MannKind (MNKD) Q1 2024 Earnings Call Transcript
May 09, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
MNKD Stock Earnings: MannKind Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
Via
InvestorPlace
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
May 08, 2024
From
MannKind
Via
GlobeNewswire
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
May 06, 2024
From
MannKind
Via
GlobeNewswire
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
May 01, 2024
From
MannKind
Via
GlobeNewswire
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
April 30, 2024
From
MannKind
Via
GlobeNewswire
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
April 29, 2024
From
MannKind
Via
GlobeNewswire
MannKind Repays Certain Debt Obligations
April 03, 2024
From
MannKind
Via
GlobeNewswire
MannKind Announces CFO Transition
March 26, 2024
From
MannKind
Via
GlobeNewswire
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 11, 2024
Via
Benzinga
Exposures
Product Safety
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
March 11, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
What's Going On With MannKind Stock?
March 11, 2024
Via
Benzinga
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
March 11, 2024
From
MannKind
Via
GlobeNewswire
Cramer Says Sprout Social Is In A 'Hot Spot,' But This Energy Stock Is 'Too Down And Out'
March 08, 2024
Via
Benzinga
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
March 05, 2024
From
MannKind
Via
GlobeNewswire
MannKind Corporation Announces Participation at Upcoming Conferences
March 04, 2024
From
MannKind
Via
GlobeNewswire
MannKind (MNKD) Q4 2023 Earnings Call Transcript
February 28, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
February 27, 2024
From
MannKind
Via
GlobeNewswire
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
February 20, 2024
From
MannKind
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
